OCUL Ocular Therapeutix, Inc.

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. Ocular Therapeutix (NASDAQ:OCUL) operates squarely at this intersection, pioneering bioresorbable hydrogel delivery systems designed to fundamentally alter how chronic retinal diseases are treated. The company’s core […]

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company’s planned submission packag

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the […]

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Ocular Therapeutix recently reported Q2 results that topped revenue and EPS expectations and shared that its pivotal phase 3 AXPAXLI trials remain on track for an FDA-aligned NDA submission targeted for Q4 2026. This combination of operational outperformance and regulatory clarity around AXPAXLI’s development path highlights how closely the company’s near-term outlook is tied to this single retinal asset. Next, we’ll examine how the strong quarterly performance and FDA-aligned AXPAXLI...

Ocular Therapeutix (OCUL) is back in focus after its Q2 report, where revenues and earnings per share surpassed analyst expectations, and management outlined progress on AXPAXLI phase 3 trials with an FDA aligned path toward an NDA in Q4 2026. See our latest analysis for Ocular Therapeutix. Ocular Therapeutix shares have been volatile, with the 30 day share price return of 29.06% and 90 day share price return of 34.63% coming after Q2 results and recent investor events, while the 1 year total...

Ocular Therapeutix now carries an updated fair value estimate of about US$27.09 per share, up from US$26.00, reflecting refreshed price target work in recent modeling. Recent Street commentary links these higher targets in the mid to high US$20s to views on Axpaxli’s market opportunity, competitive trial readouts, and the latest FDA interactions. As you read on, you will see how to track these shifting assumptions and what to watch as the Ocular Therapeutix story continues to evolve. Analyst...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Ocular Therapeutix (NASDAQ:OCUL) and its peers.

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.

Ocular Therapeutix's (OCUL) regulatory plans for Axpaxli in wet age-related macular degeneration rem

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 17% over the past six months while the S&P 500 was up 8.3%.

Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $13.48 million. Its GAAP loss of $0.35 per share was 11.2% above analysts’ consensus estimates.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season.

Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.